Avadomide
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Avadomide
- DrugBank Accession Number
- DB14857
- Background
Avadomide is under investigation in clinical trial NCT02031419 (Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 286.291
Monoisotopic: 286.106590327 - Chemical Formula
- C14H14N4O3
- Synonyms
- 3-(5-Amino-2-methyl-4-oxo-4H-quinazolin-3-yl)piperidine-2,6-dione
- Avadomide
- External IDs
- CC-122
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Avadomide hydrochloride 6CX4AEX3KR 1398053-45-6 BVJRNKXVSYLNFD-UHFFFAOYSA-N
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 28DZS29F59
- CAS number
- 1015474-32-4
- InChI Key
- RSNPAKAFCAAMBH-UHFFFAOYSA-N
- InChI
- InChI=1S/C14H14N4O3/c1-7-16-9-4-2-3-8(15)12(9)14(21)18(7)10-5-6-11(19)17-13(10)20/h2-4,10H,5-6,15H2,1H3,(H,17,19,20)
- IUPAC Name
- 3-(5-amino-2-methyl-4-oxo-3,4-dihydroquinazolin-3-yl)piperidine-2,6-dione
- SMILES
- CC1=NC2=C(C(N)=CC=C2)C(=O)N1C1CCC(=O)NC1=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0249718
- ChemSpider
- 35521266
- BindingDB
- 76986
- ChEMBL
- CHEMBL3989934
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Melanoma 1 1 Active Not Recruiting Treatment Non-Hodgkin's Lymphoma (NHL) 1 1 Completed Other Clinical Pharmacology, Healthy Male Volunteer Study 1 1 Completed Other Healthy Volunteers (HV) 1 1 Completed Treatment Diffuse Large B-Cell Lymphoma (DLBCL) / High Grade Glioma: Glioblastoma (GBM) / Lymphoma / Multiple Myeloma (MM) / Pleiotropic Pathway Modifier / Primary Central Nervous System Lymphoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.355 mg/mL ALOGPS logP 0.06 ALOGPS logP -0.083 Chemaxon logS -2.9 ALOGPS pKa (Strongest Acidic) 11.61 Chemaxon pKa (Strongest Basic) 5.39 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 104.86 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 77.1 m3·mol-1 Chemaxon Polarizability 28.19 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-c016899953be36bbbbb8 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-000i-0090000000-c25a5a2ead1ef94638d4 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-000i-0290000000-64d86e347d2469efcc8e Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-07bu-1290000000-1203f6c21596414bfc54 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-001r-1940000000-fcfb01da1cef12e2bf92 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-00dl-3920000000-f58e5b0b652ebabd8286 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 20, 2019 14:31 / Updated at September 28, 2023 05:47